Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals Appointment strengthens confidence in clinical readiness and…
Read More
Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRD Heidelberg, Germany – 17 February 2026 – FundaMental…
Read More
Highly experienced biotech executive, with over a quarter of a century of CNS drug discovery experience Beher takes over the role of Chief Executive Officer…
Read More
Appointment underscores FundaMental’s ambition to develop medicines for neurodegenerative diseases based on a breakthrough molecular mechanism Heidelberg, GERMANY, 20 March 2024 - FundaMental Pharma GmbH,…
Read More
Heidelberg, Germany – 17 November 2022 – FundaMental Pharma GmbH (“FundaMental”), a preclinical neuroscience company spun out of Heidelberg University, today announces that it has launched…
Read More
